| Type: |
Conjugated Primary Antibody |
| Conjugated with: |
594, ALEXA FLUOR® |
| Host organism: |
Rabbit (Oryctolagus cuniculus) |
| Target Protein/Peptide: |
CLN5 |
| Specificity: |
This antibody reacts specifically with CLN5 |
| Modification: |
No modification has been applied to this antibody |
| Modification site: |
None |
| Clonality: |
Polyclonal Antibody |
| Clone: |
Polyclonal Antibodies |
| Concentration: |
1ug per 1ul |
| Antigen Source: |
KLH conjugated synthetic peptide derived from human CLN5 |
| Applications: |
IF(IHC-P) |
| Applications with corresponding dilutions: |
IF(IHC-P)(1:50-200) |
| Cross reactive species: |
Mouse (Mus musculus), Rat (Rattus norvegicus), Human (Homo sapiens) |
| Cross Reactive Species details: |
However, note that due to limited knowledge it is impossible to predict with 100% guarantee that the antibody does not corss react with any other species, No significant cross reactivity has been observed for this antibody for the tested species |
| Background information: |
A single base duplication mutation in dog and cow CLN5 has been shown to cause NCL, CLN2 (encodeing the serine protease TPP1), CLN3, CLN5, CLN6 and CLN8, Mutations in six of these genes results in a distinct type of NCL-disease, NCL is characterized by atrophy of the brain and an accumulation of lysosome derived fluorescent bodies found in many cells, Symptoms of NCL include a failure of psychomotor development, The eight genes/proteins associated with NCL are designated CLN1-CLN8, a protein thiolesterase), also designated Batten disease, comprises a group of recessively inherited, especially neurons, impaired vision and premature death, progressive neurodegenerative diseases found in children, seizures, the six genes/proteins are CLN1 (encoding PPT1, Neuronal ceroid-lipofuscinose (NCL) |
| Purification method: |
Purified by Protein A |
| Storage: |
50% glycerol and 0, Store at 4°, 09% sodium azide, C for 12 months, Water buffered solution containing 100ug/ml BSA |
| Excitation emission: |
590nm/617nm |
| Also known as: |
CLN5 Polyclonal Antibody |
| Other name: |
Anti-CLN5 Polyclonal |
| Advisory: |
For antibodies that are in liquid form or reconstituted lyophilized antibodies small amounts could become entrapped on the seal or the walls of the tube, Prior to use briefly centrifuge the vial to gather all the solution on the bottom, specificity and sensitivity, thus reducing its reactivity, Avoid freeze/thaw cycles as they may denaturate the polypeptide chains of the antibody |
| Properties: |
For facs or microscopy Alexa 1 conjugate |
| Conjugation: |
Alexa Fluor |
| Group: |
Polyclonals and antibodies |
| About: |
The advantage is that there are more epitopes available in a polyclonal antiserum to detect the proteins than in monoclonal sera, immunohistochemistry on frozen slices or parrafin fixed tissues, Polyclonals can be used for Western blot |
| Gene target: |
CLN5 |
| Short name: |
Anti-CLN5 (Polyclonal) Fluor 594 |
| Technique: |
Pabs are a collection of immunoglobulin , Polyclonal antibodies , each identifying a different , whereas , (pAbs) are mostly rabbit or goat , B cells, Polyclonal, antibodies , antigen, come from a single N cell lineage, epitope, molecules that react against a specific , monoclonal antibodies , that are secreted by different |
| Label: |
ALEXA |
| Alternative name: |
ALEXA Fluor 594, antibody to-CLN5 (polyclonal) |
| Alternative technique: |
polyclonals |
| Identity: |
2076 |
| Gene: |
CLN5 |
More about : CLN5 |
| Long gene name: |
ceroid-lipofuscinosis, neuronal 5 |
| Locus: |
13q22, 3 |
| Discovery year: |
1993-11-03 |
| Entrez gene record: |
1203 |
| Pubmed identfication: |
7942847 8661106 |
| RefSeq identity: |
NM_006493 |
| Havana BLAST/BLAT: |
OTTHUMG00000017100 |
| Locus Specific Databases: |
NCL Mutations LRG_692 , Neuronal Ceroid Lipofuscinoses |